Rallybio Corp Total Assets
Rallybio Corp total assets. Based on the latest financial reports, Rallybio Corp (RLYB) holds total assets worth $98.06 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Rallybio Corp market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Rallybio Corp (2019–2025)
Total assets of Rallybio Corp from 2019 to 2025. This chart illustrates how Rallybio Corp's total assets have evolved over time, based on quarterly financial data. See Rallybio Corp stock quote for real-time trading data and today's change.
Rallybio Corp - Asset Composition Analysis
Rallybio Corp Total Assets Breakdown (December 2025)
Rallybio Corp total assets breakdown as of December 2025. Rallybio Corp's total assets of $98.06 Million consist of 98.4% current assets and 1.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Rallybio Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Rallybio Corp current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rallybio Corp's current assets represent 98.4% of total assets in 2025, an increase from 96.8% in 2019.
- Cash Position: Cash and equivalents constituted 50.4% of total assets in 2025, down from 90.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Rallybio Corp Competitors by Total Assets
Key competitors of Rallybio Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Rallybio Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 27.26 | 9.98 | 26.20 |
| Quick Ratio | 27.26 | 9.98 | 26.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $93.69 Million | $45.23 Million | $185.05 Million |
Rallybio Corp - Advanced Valuation Insights
This section examines the relationship between Rallybio Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 1.35 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | $62.26 Million |
| Market Capitalization | $84.22 Million USD |
Valuation Analysis
Above Book Valuation: The market values Rallybio Corp's assets above their book value (1.35x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Rallybio Corp's assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Rallybio Corp (2019–2025)
The table below shows the annual total assets of Rallybio Corp from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $62.26 Million | -8.58% |
| 2024-12-31 | $68.11 Million | -41.09% |
| 2023-12-31 | $115.62 Million | -35.92% |
| 2022-12-31 | $180.44 Million | -0.96% |
| 2021-12-31 | $182.19 Million | +28.43% |
| 2020-12-31 | $141.86 Million | +556.54% |
| 2019-12-31 | $21.61 Million | -- |
About Rallybio Corp
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical … Read more